Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019027853) DETECTION OF HIGH RISK ARTERIAL THROMBOEMBOLIC DISEASES BY MARKERS OF COAGULATION AND HEMOSTATIC ACTIVATION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/027853 International Application No.: PCT/US2018/044269
Publication Date: 07.02.2019 International Filing Date: 29.07.2018
IPC:
A01K 67/027 (2006.01) ,A61K 38/54 (2006.01) ,A61K 38/57 (2006.01) ,A61K 39/395 (2006.01) ,C07K 16/24 (2006.01) ,C12P 21/08 (2006.01)
A HUMAN NECESSITIES
01
AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
K
ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
67
Rearing or breeding animals, not otherwise provided for; New breeds of animals
027
New breeds of vertebrates
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43
Enzymes; Proenzymes; Derivatives thereof
54
Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44-A61K38/46 or A61K38/51-A61K38/53186
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
55
Protease inhibitors
57
from animals; from humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
P
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21
Preparation of peptides or proteins
08
Monoclonal antibodies
Applicants:
NAHAB, Fadi Basil [US/US]; US
Inventors:
NAHAB, Fadi Basil; US
Agent:
GILES, Brian P.; Thomas Horstemeyer LLP 3200 Windy Hill Road SE Suite 1600E Atlanta, Georgia 30339, US
Priority Data:
62/538,99531.07.2017US
Title (EN) DETECTION OF HIGH RISK ARTERIAL THROMBOEMBOLIC DISEASES BY MARKERS OF COAGULATION AND HEMOSTATIC ACTIVATION
(FR) DÉTECTION DE MALADIES THROMBO-EMBOLIQUES ARTÉRIELLES À HAUT RISQUE PAR DES MARQUEURS DE COAGULATION ET D'ACTIVATION HÉMOSTATIQUE
Abstract:
(EN) Disclosed herein is a method for identifying patients with cryptogenic stroke or embolic stroke of undetermined source (ESUS) who are at risk for having occult atrial fibrillation, underlying malignancy, and/or recurrent arterial thromboembolic events. Also disclosed is a method for determining who among these patients will benefit from anticoagulants. Also disclosed herein is a method to predict whether the anticoagulant is sufficiently effective to reduce the activated coagulation system in a patient. Also disclosed herein is a method for identifying patients with cardiovascular and cerebrovascular arterial diseases who have occult atrial fibrillation, underlying but unrecognized malignancy, and/or are at high risk of recurrent arterial thromboembolic events.
(FR) La présente invention concerne un procédé pour identifier des patients ayant subi un accident vasculaire cérébral cryptogénique ou un accident vasculaire cérébral embolique de source non déterminée (ESUS) qui présentent un risque d'avoir une fibrillation auriculaire occulte, une malignité sous-jacente et/ou des événements thrombo-emboliques artériels récurrents. L'invention concerne également un procédé pour déterminer lequel de ces patients tirera un bénéfice d'anticoagulants. La présente invention concerne également un procédé pour prédire si l'anticoagulant est suffisamment efficace pour réduire le système de coagulation activé chez un patient. La présente invention concerne également un procédé pour identifier des patients atteints de maladies artérielles cardiovasculaires et cérébrovasculaires qui ont une fibrillation auriculaire occulte, une malignité sous-jacente mais non reconnue, et/ou présentent un risque élevé d'événements thrombo-emboliques artériels récurrents.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)